Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

Tubulis today announced the formation of a Scientific Advisory Board (SAB) with the appointment of international industry experts in the development of antibody drug conjugates (ADCs) and in-depth knowledge in the therapeutic areas of oncology and hematology.